Trisalus Life Sciences, Inc. <TLSI.O>: H.C. Wainwright Initiates Coverage With Buy Rating and Target Price $11
TLSI•Related News
Oil prices fly blind as the Hormuz enigma deepens: Bousso
XLE•
Plains All American buys remaining EPIC Crude Holdings stake, takes full ownership of Cactus III pipeline operator
PAA•
Apple expected to unveil first folding phone, with new CEO Ternus in command
AAPL•
Barclays downgrades US utilities sector to neutral from positive
XLU•
Chime Financial, Inc. <CHYM.O>: Barclays raises target price to $40 from $33
CHYM•